• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

Dossier.org

Market Intelligence

  • About
    • How to structure intent in Memorandum of Understanding (MOU)
  • Market Dossier
    • Technology Dossier
    • Events
    • Venture Capital Dossier
  • Domain Dossier
  • Sponsored Post
    • Make a Contribution
  • Contact

Vedanta Biosciences Raises $27 Million Series C Financing to Advance Clinical Pipeline of Microbiome-Derived Product Candidates

December 24, 2018 By admin Leave a Comment

Participants include the Bill & Melinda Gates Foundation, Bristol-Myers Squibb, Rock Springs Capital, Invesco Asset Management, Seventure, and PureTech Health

-Vedanta Biosciences, a clinical-stage company developing a new category of therapies for immune-mediated diseases based on rationally-defined consortia of human microbiome-derived bacteria, today announced that it has raised $27 million in a Series C financing with participation from new and existing strategic and institutional investors, including the Bill & Melinda Gates Foundation, Bristol-Myers Squibb, Rock Springs Capital, Invesco Asset Management, Seventure Partners, and PureTech Health. Proceeds from the financing will be used to advance Vedanta Biosciences’ pipeline of microbiome-derived product candidates, including a Phase 1/2 study of VE416 in food allergy, a Phase 1b/2 study of VE800 and Opdivo (nivolumab) in advanced or metastatic cancers, and the recently initiated Phase 2 study of VE303 in recurrent Clostridium difficile infection (rCDI).

Unlike single strain or microbiome-derived metabolite approaches to microbiome modulation, Vedanta Biosciences is developing consortia of bacterial strains designed to effect robust and durable therapeutic changes in a patient’s gut microbiota. In contrast to fecal transplants or administration of fecal fractions, Vedanta Biosciences’ consortia are defined compositions of bacteria manufactured from pure, clonal cell banks, bypassing the need to rely on direct sourcing of fecal donor material of inconsistent composition.

“We are pleased to have the support of our new and existing investors as we continue to build on our leadership position in the microbiome field,” said Bernat Olle, Ph.D., Co-founder and Chief Executive Officer of Vedanta Biosciences. “We have demonstrated that rationally-defined bacterial consortia as a new drug modality can be safe, well-tolerated, and have favorable pharmacokinetics and pharmacodynamics in humans. These new funds, together with our partnerships with Janssen and Bristol-Myers Squibb, will help us advance four programs to clinical endpoints in recurrent C. difficile infection, food allergy, IBD, and several cancer indications.”

About Vedanta Biosciences
Vedanta Biosciences is a clinical-stage company developing a new category of therapies for immune-mediated diseases based on rationally-defined consortia of human microbiome-derived bacteria. Vedanta Biosciences is a leader in the microbiome field with capabilities and deep expertise to discover, develop, and manufacture live bacteria drugs. These include what is believed to be the largest collection of human microbiome-associated bacterial strains, a suite of proprietary assays to select pharmacologically potent strains, vast proprietary datasets from human interventional studies, and facilities for cGMP-compliant manufacturing of rationally-defined bacterial consortia in powder form. Vedanta Biosciences’ pioneering work, in collaboration with its scientific co-founders, has led to the identification of human commensal bacteria that induce a range of immune responses – including induction of regulatory T cells, CD8+ T cells, and Th17 cells, among others. These advances have been published in leading peer-reviewed journals, including Science (multiple), Nature (multiple), Cell, and Nature Immunology. Vedanta Biosciences has harnessed these biological insights and its capabilities to generate a pipeline of programs in autoimmune disease, allergy, infectious disease, and immuno-oncology.

Vedanta Biosciences was founded by PureTech Health (PRTC.L). Its scientific co-founders are world-renowned experts in immunology and microbiology who have pioneered the fields of innate immunity, Th17 and regulatory T cell biology, and include Ruslan Medzhitov, Ph.D., (Yale and Howard Hughes Medical Institute (HHMI)), Brett Finlay, Ph.D., (University of British Columbia and HHMI), Kenya Honda, Ph.D., (inventor of Vedanta Biosciences’ lead product candidate; Keio University and RIKEN), Dan Littman, Ph.D., (New York University and HHMI), Alexander Rudensky, Ph.D., (Sloan Kettering and HHMI), and Jeremiah Faith, Ph.D., (Mount Sinai School of Medicine).

Filed Under: News

Reader Interactions

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Primary Sidebar

VC

NEA leads $70 M USD Series C round in Indonesian Social Commerce Platform, Super
Canditech raises $9 million seed round from Insight Partners and StageOne Ventures to create a world without resumes
Clerk Announces $6.2M Seed Funding To Build Authentication And User Management Tools For React
Cloudflare Announces $1.25 Billion “Workers Launchpad” Funding Program to Help Startups Grow Their Businesses
AI21 Labs Raises $64 Million to Change the Way People Read and Write Using Artificial Intelligence
Thought Machine Raises $160m in Series D Funding Round – Doubling Valuation to $2.7bn and Accelerating Plans to Bring World’s Banks Onto Cloud Technology
Ottopia announces $14.5M Series A Funding Round

Technologies

Researchers Identify Brain Markers of ADHD in Children
Apple Introduces Next-Generation iPad Pro, Supercharged by the M2 Chip
How Japan’s wagyu farms are going high tech
Meet the BLOOM: The Next Generation of Large Language Models
AWS Announces AWS SimSpace Weaver
BIRD – Israel-U.S. Binational Industrial R&D Foundation to invest $7.9 million in 9 new projects: The approved projects, with an overall budget of $20 million, involve innovations in the areas of Drones, Energy Efficiency, Environment Protection, Medical Devices, Pharma, Software and AI
Samsung Electronics Begins Mass Production of 8th-Gen Vertical NAND with Industry’s Highest Bit Density

Secondary Sidebar

Analysis

60% of Employees Using AI Regard It as a Coworker, Not a Job Threat
EG Radius Brings Market Analytics to the Commercial Real Estate Market
The global supply squeeze
Russia’s economy is imploding
Seegene’s COVID-19 test with saliva sample collection feature now available in Europe

Market Research

Russian oil production succumbing to the impact of Western sanctions
Global entertainment & media revenues surge to $2.3 trillion; virtual reality sees 36% growth as gaming and esports are on pace to become a $324 billion business: PwC
AfricanInvesting.com (African Investing): Africa VC Funding Grew Exponentially in 2016-2021
How to encourage creative behavior at work
Global assets under management (AuM) grew at 12% to more than $112 Trillion in 2021

Footer

Recent Posts

  • Why UK faces chronic labor shortages
  • Battery Ventures Announces Sale of Physical-Security Technology Firm Qognify to Hexagon AB
  • impak Ratings acquires Exerica, a London-based fintech data extraction firm
  • Kentucky’s Wilderness Trail bourbon distillery to be sold to Italian maker of Campari
  • Container xChange Survey: 60% of Freight Forwarders and NVOCCs Struggle to Monitor Movement of Shipping Containers
  • Cloud storage company Box can surge nearly 40% on the future of work
  • Rockwell Automation Announces Intent to Acquire CUBIC
  • Vianode invests NOK 2 billion in battery materials plant in Norway
  • 69% of investors are betting the euro will slide to $0.9
  • Defense Market, July 2022

RSS Blockchaining

  • Blockchain topics to be covered at DLD 2023
  • Experience the Future of Blockchain at Cybertech 2023
  • Join Our Team as a Blockchain Developer - Revolutionize the Future
  • The Fascinating World of Cryptocurrency
  • State of Technology Overview: Blockchaining 2023

RSS S3H

  • Join Our Team at S3H.com Consulting - A One-Stop Shop for Technology Solutions
  • Cybertech 2023
  • Winner-take-all: GAFA vs BATX
  • Technology Events
  • The China smartphone market has hit a decade-long low in 2022

RSS VPNW

  • Unlock Your Creativity with a Competitive Mindset
  • Start today and make exercise a part of your daily routine
  • If hard work meant success, the donkey would own the farm
  • The Benefits of Mindfulness Meditation
  • The Rise of Plant-Based Diets

RSS OPINT

  • North Korea is working to create a nuclear warfighting capability
  • China’s proliferation of nuclear and missile-related technologies to other countries
  • The United States has been a major supporter of Ukraine’s security
  • The Impact of the Middle East on Global Geopolitics
  • The Impact of the Belt and Road Initiative on Global Geopolitics

Copyright © 2022 Dossier.org

Technologies, Market Analysis & Market Research and Exclusive Domains

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
Cookie SettingsAccept
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT